Claudin 18.2 在胃腺癌和食管腺癌中的预后影响。
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.
机构信息
Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Gastroenterology, Infectious Diseases and Rheumatology. Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
出版信息
Clin Transl Oncol. 2020 Dec;22(12):2357-2363. doi: 10.1007/s12094-020-02380-0. Epub 2020 Jun 1.
INTRODUCTION
The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S).
METHODS
This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients.
RESULTS
Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly (p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor with overall survival.
CONCLUSION
In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.
简介
紧密连接分子 Claudin 18.2 选择性地表达于健康和恶性胃上皮组织，是治疗胃食管结合部和胃高表达 Claudin 18.2 腺癌（AEG/S）的有前途的治疗靶点。
方法
本研究分析了 414 例高加索 AEG/S 患者中 Claudin 18.2 在原发性肿瘤、淋巴结和远处转移中的表达频率、特征和预后影响。
结果
Claudin 18.2 在原发性肿瘤中的表达率为 17.1%，在淋巴结转移中的表达率为 26.7%，在远处转移中的表达率为 16.7%。淋巴结转移和原发性肿瘤中 Claudin 18.2 的高表达显著相关（p<0.001）。 Claudin 18.2 的高表达与组织形态亚型、肿瘤状态或总生存均无相关性。
结论
在高加索裔 AEG/S 患者中，有 17.1%的患者可能适合接受抗 Claudin 18.2 治疗。 Claudin 18.2 的表达本身对预后没有影响，也与任何肿瘤亚型无关。
Zotero 插件